IQVIA Holdings Inc. Stock
Price
Target price
€177.55
€177.55
5.000%
8.45
5.000%
-
16:26 / Tradegate
WKN: A2JSPM / Name: IQVIA / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock IQVIA Holdings Inc. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for IQVIA
sharewise wants to provide you with the best news and tools for IQVIA, so we directly link to the best financial data sources.
Financials
News
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Key Points
- Interested in Amphastar Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amphastar reaffirmed its expectation for mid- to high-single-digit revenue growth in 2026, with
IQVIA Q1 Earnings Call Highlights
IQVIA (NYSE:IQV) reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing
ANI Pharmaceuticals Q1 Earnings Call Highlights
ANI Pharmaceuticals (NASDAQ:ANIP) reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease
Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors
Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech